2021
Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso
Compaoré Y, Zongo I, Somé A, Barry N, Nikiéma F, Kaboré T, Ouattara A, Kabré Z, Wermi K, Zongo M, Yerbanga R, Sagara I, Djimdé A, Ouédraogo J. Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso. Malaria Journal 2021, 20: 64. PMID: 33514368, PMCID: PMC7847156, DOI: 10.1186/s12936-021-03593-6.Peer-Reviewed Original ResearchConceptsHepatic adverse eventsArtemether-lumefantrineAL armAdverse eventsElevated ALTMalaria episodesUncomplicated malariaHepatic safetyDirect bilirubinPA armFirst-line anti-malarial drugHepatic safety profileUncomplicated malaria episodesElevated total bilirubinBobo-DioulassoLogistic regression modelsAnti-malarial drugsAlkaline phosphataseSubsequent malariaUnscheduled daysStudy armsSafety profileResultsA totalClinical trialsTotal bilirubin
2020
Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study
Partnership A, Baba E, Hamade P, Kivumbi H, Marasciulo M, Maxwell K, Moroso D, Roca-Feltrer A, Sanogo A, Johansson J, Tibenderana J, Abdoulaye R, Coulibaly P, Hubbard E, Jah H, Lama E, Razafindralambo L, Van Hulle S, Jagoe G, Tchouatieu A, Collins D, Gilmartin C, Tetteh G, Djibo Y, Ndiaye F, Kalleh M, Kandeh B, Audu B, Ntadom G, Kiba A, Savodogo Y, Boulotigam K, Sougoudi D, Guilavogui T, Keita M, Kone D, Jackou H, Ouba I, Ouedraogo E, Messan H, Jah F, Kaira M, Sano M, Traore M, Ngarnaye N, Elagbaje A, Halleux C, Merle C, Iessa N, Pal S, Sefiani H, Souleymani R, Laminou I, Doumagoum D, Kesseley H, Coldiron M, Grais R, Kana M, Ouedraogo J, Zongo I, Eloike T, Ogboi S, Achan J, Bojang K, Ceesay S, Dicko A, Djimde A, Sagara I, Diallo A, NdDiaye J, Loua K, Beshir K, Cairns M, Fernandez Y, Lal S, Mansukhani R, Muwanguzi J, Scott S, Snell P, Sutherland C, Tuta R, Milligan P. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. The Lancet 2020, 396: 1829-1840. PMID: 33278936, PMCID: PMC7718580, DOI: 10.1016/s0140-6736(20)32227-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAfrica, CentralAfrica, WesternAmodiaquineAntimalarialsCase-Control StudiesChemopreventionChildCost-Benefit AnalysisDrug CombinationsDrug ResistanceFeasibility StudiesHumansIncidenceMalariaProgram EvaluationPyrimethamineSafetySeasonsSulfadoxineSurveys and QuestionnairesYoung AdultConceptsSeasonal malaria chemopreventionCase-control studyHigh transmission periodMalaria chemopreventionObservational studyHealth-care staff timeHigh malaria transmission seasonDrug resistanceSerious adverse drug reactionsMalaria transmission seasonSerious adverse reactionsSevere skin reactionsCommunity health workersNational health management information systemAdverse drug reactionsCost-effectiveness ratioHealth Management Information SystemIndividual case safetyTarget populationMarker of resistanceSMC treatmentHospital admissionOutpatient clinicDrug reactionsSkin reactionsEfficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change
Zongo I, Compaoré Y, Nikiéma F, Zongo M, Barry N, Somé F, Kaboré N, Ouédraogo J. Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change. Pan African Medical Journal 2020, 35: 68. PMID: 32537072, PMCID: PMC7250195, DOI: 10.11604/pamj.2020.35.68.20849.Peer-Reviewed Original ResearchConceptsFirst-line therapyLine therapyUncomplicated malariaPolymerase chain reactionTreatment efficacyEarly treatment failureGood tolerability profileFirst-line treatmentParasitological responsePrimary endpointTolerability profileArtemether-lumefantrineTreatment failureLine treatmentASAQ groupDay 28Better efficacyBurkina FasoTherapyMalariaEfficacyChain reactionCompletion ratesTreatmentDaysIn vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso
Lingani M, Bonkian L, Yerbanga I, Kazienga A, Valéa I, Sorgho H, Ouédraogo J, Mens P, Schallig H, Ravinetto R, d’Alessandro U, Tinto H. In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malaria Journal 2020, 19: 8. PMID: 31906948, PMCID: PMC6945612, DOI: 10.1186/s12936-019-3089-z.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsArtesunateBurkina FasoChildChild, PreschoolDrug CombinationsDrug Therapy, CombinationFemaleHumansInfantInhibitory Concentration 50LumefantrineMalaria, FalciparumMaleMass Drug AdministrationPlasmodium falciparumTreatment FailureTreatment OutcomeConceptsFirst-line treatmentArtemether-lumefantrineUncomplicated malariaFalciparum malariaTreatment failureOverall adverse event incidenceUncomplicated Plasmodium falciparum malariaEx vivo efficacyUnadjusted cure rateAdverse event incidenceUncomplicated falciparum malariaPlasmodium falciparum malariaP. falciparum susceptibilityMalaria-endemic areasEx vivo susceptibilityMass drug administrationP. falciparum isolatesEx vivo analysisAL armASAQ armOpen labelPrimary endpointRecurrent parasitaemiaEvent incidenceTreatment arms
2019
Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method
Funck-Brentano C, Ouologuem N, Duparc S, Felices M, Sirima S, Sagara I, Soulama I, Ouedraogo J, Beavogui A, Borghini-Fuhrer I, Khan Y, Djimdé A, Voiriot P. Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method. Scientific Reports 2019, 9: 883. PMID: 30696921, PMCID: PMC6351684, DOI: 10.1038/s41598-018-37113-5.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyQTc prolongationHeart rate changesCombination therapyVentricular repolarizationQT/QTc interval prolongationEvidence of proarrhythmiaQTc interval prolongationQTc assessmentLethal ventricular arrhythmiasExtent of prolongationMalaria crisisArtemether-lumefantrineInterval prolongationVentricular arrhythmiasAfrican patientsClinical safetyFirst episodeQT intervalHeart rateAntimalarial drugsProlongationQT correctionECG recordingsHigh-quality ECG recording
2018
Serum Carotenoids Reveal Poor Fruit and Vegetable Intake among Schoolchildren in Burkina Faso
Bationo J, Zeba A, Abbeddou S, Coulibaly N, Sombier O, Sheftel J, Bassole I, Barro N, Ouedraogo J, Tanumihardjo S. Serum Carotenoids Reveal Poor Fruit and Vegetable Intake among Schoolchildren in Burkina Faso. Nutrients 2018, 10: 1422. PMID: 30287727, PMCID: PMC6213241, DOI: 10.3390/nu10101422.Peer-Reviewed Original ResearchConceptsSerum retinol concentrationsSerum carotenoidsRetinol concentrationsVegetable intakeLow serum carotenoidsSerum carotene concentrationSerum carotenoid concentrationsTotal serum carotenoid concentrationsLow serum vitaminCross-sectional studyIndividual carotenoid concentrationsΒ-cryptoxanthinHabitual intakeSerum vitaminHigh prevalenceLow intakeReference rangeVitamin A.IntakeHealth benefitsRich fruitsCarotenoid concentrationsBurkina FasoHigh-performance liquid chromatographySchoolchildrenAntibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign?
Yaro S, Lafourcade B, Ouangraoua S, Ouoba A, Kpoda H, Findlow H, Tall H, Seanehia J, Martin C, Ouedraogo J, Gessner B, Meda N, Borrow R, Trotter C, Mueller J. Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign? Clinical Infectious Diseases 2018, 68: 435-443. PMID: 30481265, DOI: 10.1093/cid/ciy488.Peer-Reviewed Original ResearchConceptsPre-vaccination levelsAge groupsBooster campaignAntibody persistenceMeningococcal serogroup A conjugate vaccineSerum bactericidal antibody titersBactericidal antibody titersYounger age groupsOlder age groupsImmunoglobulin G concentrationCross-sectional surveyTime of returnDifferent age groupsConjugate vaccineAntibody titersImmune protectionGeneral populationMass vaccinationSerological surveyComplete returnOlder individualsMass campaignsBurkina FasoGeometric meanBobo-DioulassoPlasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso
Somé A, Bazié T, Zongo I, Yerbanga R, Nikiéma F, Neya C, Taho L, Ouédraogo J. Plasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso. Parasites & Vectors 2018, 11: 323. PMID: 29843783, PMCID: PMC5975679, DOI: 10.1186/s13071-018-2895-4.Peer-Reviewed Original ResearchConceptsSymptomatic malaria patientsPolymerase chain reactionMalaria patientsAllelic familiesBobo-DioulassoMAD20 allelic familyUrban health centersCause of morbidityMerozoite surface protein 1K1 allelic familySurface protein 1Plasmodium falciparum msp1P. malariaUncomplicated malariaFalciparum infectionResultsA totalHealth centersBlood samplesP. falciparumConclusionsOur studyBlood spotsMalaria parasite populationsAllele frequenciesPatientsBurkina FasoPyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial
Drugs T, Sagara I, Beavogui A, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Traore A, Diallo N, Diakite H, Togo A, Koumare S, Keita M, Camara D, Somé A, Coulibaly A, Traore O, Dama S, Goita S, Djimde M, Bamadio A, Dara N, Maiga H, Sidibe B, Dao F, Coulibaly M, Alhousseini M, Niangaly H, Sangare B, Diarra M, Coumare S, Kabore M, Ouattara S, Barry A, Kargougou D, Diarra A, Henry N, Soré H, Bougouma E, Thera I, Compaore Y, Sutherland C, Sylla M, Nikiema F, Diallo M, Dicko A, Picot S, Borrmann S, Duparc S, Miller R, Doumbo O, Shin J, Gil J, Björkman A, Ouedraogo J, Sirima S, Djimde A. Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. The Lancet 2018, 391: 1378-1390. PMID: 29606364, PMCID: PMC5889791, DOI: 10.1016/s0140-6736(18)30291-5.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyFirst-line artemisinin-based combination therapyArtemether-lumefantrineDay 28Day 42Study drugUncomplicated malariaMalaria episodesEligible participantsIncidence ratePan African Clinical Trials RegistryUncomplicated P falciparum malariaCurrent first-line therapyAfrican Clinical Trials RegistryDeveloping Countries Clinical Trials PartnershipDihydroartemisinin-piperaquine treatmentFirst malaria episodeP falciparum malariaUncomplicated malaria episodesFirst-line therapyHistory of feverClinical Trials RegistryNon-falciparum speciesMild transient elevationUK Medical Research Council
2016
Polymorphisms in K13, pfcrt, pfmdr1, pfdhfr, and pfdhps in parasites isolated from symptomatic malaria patients in Burkina Faso
Somé A, Sorgho H, Zongo I, Bazié T, Nikiéma F, Sawadogo A, Zongo M, Compaoré Y, Ouédraogo J. Polymorphisms in K13, pfcrt, pfmdr1, pfdhfr, and pfdhps in parasites isolated from symptomatic malaria patients in Burkina Faso. Parasite 2016, 23: 60. PMID: 28004634, PMCID: PMC5178381, DOI: 10.1051/parasite/2016069.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, BacterialAntigens, SurfaceAntimalarialsArtemisininsBurkina FasoChildChild, PreschoolDrug ResistanceDrug Therapy, CombinationHumansInfantMalaria, FalciparumMembrane Transport ProteinsMultidrug Resistance-Associated ProteinsPlasmodium falciparumPolymorphism, Single NucleotideProtozoan ProteinsYoung AdultConceptsPolymerase chain reactionUncomplicated malariaDrug resistance polymorphismsPfcrt 76TResistance-mediating polymorphismsPrevalence of polymorphismsSymptomatic malaria patientsAntimalarial drug resistanceGlobal malaria controlEmergence of resistancePfmdr1 184FPfmdr1 86YMalaria patientsPfdhps genesBaseline prevalenceCombination therapyHealth centersBlood samplesWestern CambodiaBetter efficacyGene polymorphismsCodon 540Malaria controlDrug resistancePfdhps
2015
Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso
Tall H, Yaro S, Kpoda H, Ouangraoua S, Trotter C, Lafourcade B, Findlow H, Bai X, Martin C, Nwakamma I, Ouedraogo J, Gessner B, Borrow R, Mueller J. Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso. Clinical Infectious Diseases 2015, 61: s540-s546. PMID: 26553686, PMCID: PMC4639492, DOI: 10.1093/cid/civ519.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnimalsAntibodies, BacterialBlood Bactericidal ActivityBurkina FasoChildChild, PreschoolComplement System ProteinsFemaleHumansImmunoglobulin GInfantMaleMass VaccinationMeningitis, MeningococcalMeningococcal VaccinesNeisseria meningitidis, Serogroup ARabbitsSeroepidemiologic StudiesYoung AdultConceptsAntibody titersSerum bactericidal antibody titersVaccine-eligible age groupsBactericidal antibody titersGeometric mean titersAfrican meningitis beltPopulation-level immunitySpecific antibody titersMass immunization campaignOptimal vaccination strategyImmunoglobulin G concentrationLong-term controlPsA-TTMean titersVaccine coverageProtective antibodiesMeningitis beltBlood drawVaccination strategiesImmunization campaignRabbit complementGroup AHigh seroprevalenceStandardized interviewAge groupsSafety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial
Sagara I, Beavogui A, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Camara D, Somé A, Coulibaly A, Traore O, Dara N, Kabore M, Thera I, Compaore Y, Sylla M, Nikiema F, Diallo M, Dicko A, Gil J, Borrmann S, Duparc S, Miller R, Doumbo O, Shin J, Bjorkman A, Ouedraogo J, Sirima S, Djimdé A. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. The Lancet Infectious Diseases 2015, 16: 189-198. PMID: 26601738, PMCID: PMC4726763, DOI: 10.1016/s1473-3099(15)00318-7.Peer-Reviewed Original ResearchConceptsSubstudy analysisFirst episodeFirst treatmentArtemisinin-based combination treatmentDeveloping Countries Clinical Trials PartnershipPrimary safety endpointPyronaridine-artesunate efficacyHistory of feverIncidence of hepatotoxicityAdverse event frequencyExclusion of patientsUK Medical Research CouncilMedical Research CouncilParasitological responseSafety endpointArtemether-lumefantrineMalaria episodesTreat analysisAfrican patientsMalaria treatmentClinical trialsMalaria VentureLaboratory valuesAlanine aminotransferaseHealth facilities
2014
Asymptomatic Malaria Infection Affects the Interpretation of Biomarkers of Iron and Vitamin A Status, Even after Adjusting for Systemic Inflammation, but Does Not Affect Plasma Zinc Concentrations among Young Children in Burkina Faso
Wessells K, Hess S, Ouédraogo Z, Rouamba N, Ouédraogo J, Brown K. Asymptomatic Malaria Infection Affects the Interpretation of Biomarkers of Iron and Vitamin A Status, Even after Adjusting for Systemic Inflammation, but Does Not Affect Plasma Zinc Concentrations among Young Children in Burkina Faso. Journal Of Nutrition 2014, 144: 2050-2058. PMID: 25411038, DOI: 10.3945/jn.114.200345.Peer-Reviewed Original ResearchMeSH KeywordsAcute-Phase ProteinsAcute-Phase ReactionAdolescentAnemia, Iron-DeficiencyAsymptomatic DiseasesBiomarkersBurkina FasoChildC-Reactive ProteinCross-Sectional StudiesDietary SupplementsFemaleFerritinsHemoglobinsHumansIron, DietaryLinear ModelsMalariaMaleMicronutrientsNutritional StatusOrosomucoidPrevalenceProteinsRandomized Controlled Trials as TopicRetinol-Binding ProteinsVitamin AVitamin A DeficiencyZincConceptsAcute phase proteinsElevated acute phase proteinsAsymptomatic malaria infectionsMalaria infectionMicronutrient statusBiomarkers of ironSoluble transferrin receptorVitamin A StatusAcute phase responseIndicators of ironPlasma zinc concentrationAsymptomatic malariaAsymptomatic childrenSystemic inflammationMalaria parasitemiaHigh prevalenceA StatusPhase proteinsInterpretation of biomarkersZinc statusIron deficiencyLower RBPHRP2PrevalenceMicronutrient deficienciesEx vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change
Tinto H, Bonkian L, Nana L, Yerbanga I, Lingani M, Kazienga A, Valéa I, Sorgho H, Kpoda H, Guiguemdé T, Ouédraogo J, Mens P, Schallig H, D’Alessandro U. Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change. Malaria Journal 2014, 13: 207. PMID: 24885950, PMCID: PMC4049403, DOI: 10.1186/1475-2875-13-207.Peer-Reviewed Original ResearchConceptsP. falciparum sensitivityVivo studiesFirst-line treatmentPlasmodium falciparum fieldAnti-malarial drugsEx vivo studyDrug sensitivity profilesDHA-PPQChloroquine resistanceIC50 valuesPartner drugsDrug efficacy testsDrug measurementsInhibitory concentration valuesMonodesethylamodiaquinePiperaquineEfficacy of ALHigher IC50 valuesPlasmodium falciparumDihydroartemisininFive yearsCellular proliferationDrugsRecent reportsLumefantrine
2013
Associations Between Intestinal Mucosal Function and Changes in Plasma Zinc Concentration Following Zinc Supplementation
Wessells K, Hess S, Rouamba N, Ouédraogo Z, Kellogg M, Goto R, Duggan C, Ouédraogo J, Brown K. Associations Between Intestinal Mucosal Function and Changes in Plasma Zinc Concentration Following Zinc Supplementation. Journal Of Pediatric Gastroenterology And Nutrition 2013, 57: 348-355. PMID: 23689263, PMCID: PMC4627695, DOI: 10.1097/mpg.0b013e31829b4e9e.Peer-Reviewed Original ResearchConceptsPlasma Zn concentrationsIntestinal mucosal functionMucosal functionCitrulline concentrationZn supplementationIntestinal function testsPlacebo-controlled trialMalabsorption of fatPlasma citrulline concentrationHealthy children 6Plasma zinc concentrationMonths of agePlacebo groupPlacebo supplementationUrinary lactuloseFunction testsIntestinal permeabilitySupplementation groupZinc supplementationChildren 6Vitamin AZinc absorptionDietary Zn absorptionSupplementationMineral absorptionRubella seroprevalence among pregnant women in Burkina Faso
Tahita M, Hübschen J, Tarnagda Z, Ernest D, Charpentier E, Kremer J, Muller C, Ouedraogo J. Rubella seroprevalence among pregnant women in Burkina Faso. BMC Infectious Diseases 2013, 13: 164. PMID: 23556510, PMCID: PMC3623657, DOI: 10.1186/1471-2334-13-164.Peer-Reviewed Original ResearchConceptsOverall seropositivity ratePregnant womenRubella seroprevalenceSeropositivity rateNon-immune pregnant womenRubella-specific IgG antibodiesOverall immunity rateOlder age groupsRubella infectionEarly pregnancyAntibody titersRoutine immunizationCommercial ELISA kitIgG antibodiesImmunity rateRubella virusAge groupsELISA kitSerum samplesBurkina FasoWomenInternational unitsSeroprevalenceHigh percentageSerious consequences
2011
Host candidate gene polymorphisms and clearance of drug-resistant Plasmodium falciparum parasites
Diakite M, Achidi E, Achonduh O, Craik R, Djimde A, Evehe M, Green A, Hubbart C, Ibrahim M, Jeffreys A, Khan B, Kimani F, Kwiatkowski D, Mbacham W, Jezan S, Ouedraogo J, Rockett K, Rowlands K, Tagelsir N, Tekete M, Zongo I, Ranford-Cartwright L. Host candidate gene polymorphisms and clearance of drug-resistant Plasmodium falciparum parasites. Malaria Journal 2011, 10: 250. PMID: 21867552, PMCID: PMC3177816, DOI: 10.1186/1475-2875-10-250.Peer-Reviewed Original ResearchConceptsDrug-resistant parasitesHuman genomeAnti-malarial drugsSignificant associationDrug treatmentResistant parasitesAnti-inflammatory cytokine responseTh1/Th2 balanceDrug-resistant Plasmodium falciparum parasitesDrug-resistant P. falciparumMolecular testsPlasmodium falciparum infectionPlasmodium falciparum parasitesDrug resistance profilesDrug-resistant infectionsImmune response lociCandidate gene polymorphismsAbility of parasitesTh2 balanceFalciparum infectionCytokine responsesMalaria infectionOdds ratioClearance phenotypeEnhanced clearance
2010
Acceptability of zinc‐fortified, lipid‐based nutrient supplements (LNS) prepared for young children in Burkina Faso
Hess S, Bado L, Aaron G, Ouédraogo J, Zeilani M, Brown K. Acceptability of zinc‐fortified, lipid‐based nutrient supplements (LNS) prepared for young children in Burkina Faso. Maternal And Child Nutrition 2010, 7: 357-367. PMID: 21159124, PMCID: PMC6860760, DOI: 10.1111/j.1740-8709.2010.00287.x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBurkina FasoConsumer BehaviorDietary FatsDietary SupplementsDose-Response Relationship, DrugFemaleFocus GroupsHumansInfantInfant FoodInfant Nutritional Physiological PhenomenaInterviews as TopicMaleMicronutrientsNutritive ValueSocioeconomic FactorsSurveys and QuestionnairesYoung AdultZincConceptsLipid-based nutrient supplementsAcceptability studyYoung childrenPublic health concernPossible adverse effectsNutrient supplementsNutritional statusComplementary foodsChildren 9Health concernLow-income countriesMaternal reportsAdverse effectsTrialsChildren's consumptionMicronutrient deficienciesMothersChildrenGood acceptabilityDoseDetectable differenceTime of consumptionSupplementsNovel strategyDetection of differencesGenetic variation in human HBB is associated with Plasmodium falciparum transmission
Gouagna L, Bancone G, Yao F, Yameogo B, Dabiré K, Costantini C, Simporé J, Ouedraogo J, Modiano D. Genetic variation in human HBB is associated with Plasmodium falciparum transmission. Nature Genetics 2010, 42: 328-331. PMID: 20305663, DOI: 10.1038/ng.554.Peer-Reviewed Original Research
2009
Phylogenetic Analysis of Human Parvovirus B19 Sequences from Eleven Different Countries Confirms the Predominance of Genotype 1 and Suggests the Spread of Genotype 3b
Hübschen J, Mihneva Z, Mentis A, Schneider F, Aboudy Y, Grossman Z, Rudich H, Kasymbekova K, Sarv I, Nedeljkovic J, Tahita M, Tarnagda Z, Ouedraogo J, Gerasimova A, Moskaleva T, Tikhonova N, Chitadze N, Forbi J, Faneye A, Otegbayo J, Charpentier E, Muller C. Phylogenetic Analysis of Human Parvovirus B19 Sequences from Eleven Different Countries Confirms the Predominance of Genotype 1 and Suggests the Spread of Genotype 3b. Journal Of Clinical Microbiology 2009, 47: 3735-3738. PMID: 19741071, PMCID: PMC2772644, DOI: 10.1128/jcm.01201-09.Peer-Reviewed Original Research